Galera Therapeutics Files 8-K
Ticker: GRTX · Form: 8-K · Filed: May 13, 2024 · CIK: 1563577
Sentiment: neutral
Topics: corporate-disclosure, address-change
TL;DR
Galera Therapeutics updated its address in an 8-K filing.
AI Summary
On May 13, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 45 Liberty Blvd, Suite 230, Malvern, PA 19355. The report does not contain specific financial results or operational updates beyond the address change.
Why It Matters
This filing serves as a notification of a change in the company's principal executive offices, which is a standard corporate disclosure.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding office location and does not contain material financial or operational information that would impact risk.
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- 45 Liberty Blvd, Suite 230, Malvern, PA 19355 (location) — Principal executive offices
- May 13, 2024 (date) — Date of report
FAQ
What is the new address for Galera Therapeutics, Inc.'s principal executive offices?
The new address for Galera Therapeutics, Inc.'s principal executive offices is 45 Liberty Blvd, Suite 230, Malvern, PA 19355.
What is the date of this 8-K filing?
The date of this 8-K filing is May 13, 2024.
What is the company's telephone number?
The company's telephone number is (610) 725-1500.
In which state was Galera Therapeutics, Inc. incorporated?
Galera Therapeutics, Inc. was incorporated in Delaware.
What is the SEC file number for Galera Therapeutics, Inc.?
The SEC file number for Galera Therapeutics, Inc. is 001-39114.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 9.3 · Accepted 2024-05-13 07:05:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX The Nasdaq
Filing Documents
- d802127d8k.htm (8-K) — 25KB
- d802127dex991.htm (EX-99.1) — 30KB
- g802127g0511013721237.jpg (GRAPHIC) — 4KB
- 0001193125-24-136687.txt ( ) — 186KB
- grtx-20240513.xsd (EX-101.SCH) — 3KB
- grtx-20240513_lab.xml (EX-101.LAB) — 18KB
- grtx-20240513_pre.xml (EX-101.PRE) — 11KB
- d802127d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release of Galera Therapeutics, Inc. issued May 13, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: May 13, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer